IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) posted its earnings results on Monday. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03, Briefing.com reports. During the same period in the prior year, the business posted ($0.46) earnings per share.

IDEAYA Biosciences Trading Down 1.4 %

NASDAQ IDYA traded down $0.42 on Tuesday, hitting $29.58. 1,118,816 shares of the company traded hands, compared to its average volume of 851,363. The business's 50 day moving average price is $32.95 and its 200-day moving average price is $36.89. IDEAYA Biosciences has a 52-week low of $27.52 and a 52-week high of $47.74. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -13.70 and a beta of 0.86.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Cantor Fitzgerald initiated coverage on shares of IDEAYA Biosciences in a report on Tuesday, October 15th. They set an "overweight" rating on the stock. Stifel Nicolaus boosted their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a "buy" rating in a report on Tuesday, September 10th. Wedbush restated an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Monday. Finally, BTIG Research lifted their target price on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of "Buy" and an average price target of $53.08.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.